Replies to post #123035 on Innovation Pharmaceuticals Inc (IPIX)

[Ernesto]

I don't believe this to be the case at least with regard to Phase 1. We already know it is safe. We already know it is effective (Orphan designation requires signs of efficacy).

Kevetrin Phase 1 success is already assumed by the market. Sadly it simply values it at less than nothing while on the pinks. Any one of our four assets is worth more than our market cap of 170M at this point. Our stock price is completely and utterly unhinged from any reasonable reality. It will remain so for as long as the powers keeping us here desire.

A reverse split pops us up above $2 for an immediate uplist followed by an immediate revaluation over $1B as institutions buy in.

I thought the 10K would result in a pop to uplist but now I believe only a deal or a RS will get us on NASDAQ. This means we will have a deal or an RS by the end of next year as Leo will not draw from the shelf or Aspire at the current prices.